Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
LONDON, BOSTON, TOKYO (December 19, 2019) – Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Evaluate Vantage 2020 Preview, published today. Vaccines and diabetes also show strong growth, the latter despite heavy competition and pricing pressure. Vertex’s Trikafta – one of the mostly valuable R&D products of 2019 – will be a top performer as well.
Despite a strong outlook for many industry segments, biopharma investors have concerns about increasing market volatility next year. Although investors have seen time-to-exit by either M&A or IPO steadily decrease, in 2019 companies took bigger discounts to proposed valuations at IPO and private investors saw smaller returns on new flotations.
“Biopharma is poised for a strong finish in 2019, but many are wondering whether the current rally can be maintained for much longer,” said Amy Brown, report author. “Political and pricing uncertainty in the US could make stock market conditions tougher next year, which would make it much harder to float, and that could have knock-on effects to other sectors, like venture financing.”
Notable Report Findings
This report is published by Evaluate Vantage, the independent editorial team at Evaluate Ltd. All data cited is from EvaluatePharma Vision, the first single view of pharmaceutical risk and return. Download the full report at: https://www.evaluate.com/Pharma2020Preview.
Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors.
Our Evaluate platform offers unique and dynamic insights into asset risk and value alongside a seamless, comprehensive view of the pharmaceutical portfolio landscape.
Evaluate Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into current and future industry developments.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.